Guidelines for the prevention, diagnosis and management of cryptococcal meningitis and disseminated cryptococcosis in HIV-infected patients

Southern African Journal of HIV Medicine

Volumn , Issue 28, 2007, Pages 25-35

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; ANTIRETROVIRUS AGENT; COTRIMOXAZOLE; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; FUNGUS ANTIBODY; HYDROCORTISONE; ISONIAZID; NEVIRAPINE; NUCLEOSIDE; OPIATE; PARACETAMOL; PREDNISONE; PYRAZINAMIDE; RIFAMPICIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; STEROID; VORICONAZOLE;

ABDOMINAL PAIN; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANEMIA; ANTIBIOTIC RESISTANCE; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CEREBROSPINAL FLUID DRAINAGE; CEREBROSPINAL FLUID EXAMINATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; CRYPTOCOCCAL MENINGITIS; CRYPTOCOCCOSIS; DIAGNOSTIC TEST; DRUG BIOAVAILABILITY; DRUG DOSE REDUCTION; DRUG INDUCED DISEASE; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENCEPHALITIS; FEVER; FUNGAL DETECTION; FUNGAL STRAIN; FUNGICIDAL ACTIVITY; FUNGUS CULTURE; FUNGUS ISOLATION; HEADACHE; HEPATITIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOKALEMIA; HYPOMAGNESEMIA; IMMUNE DEFICIENCY; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INTRACRANIAL HYPERTENSION; JAUNDICE; KIDNEY TUBULE ACIDOSIS; LIVER TOXICITY; LOW DRUG DOSE; LUMBAR PUNCTURE; LUNG CAVITATION; LUNG INFILTRATE; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; NAUSEA; NEPHROTOXICITY; PATIENT COUNSELING; PHLEBITIS; RASH; SCREENING TEST; SKIN DEFECT; TOXIC HEPATITIS; TUBERCULOSIS; VOMITING;

EID: 38048998956     PISSN: 16089693     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Mirza SA, Phelan M, Rimland D, et al. The changing epidemiology of cryptococcosis: an update from population-based active surveillance in 2 large metropolitan areas, 1992-2000. Clin Infect Dis 2003; 36(6): 789-794.
2. Friedman GD, Jeffrey FW, Udaltsova NV, Hurley LB. Cryptococcosis: the 1981-2000 epidemic. Mycoses 2005; 48(2): 122-125.
3. Dromer F, Mathoulin S, Dupont B, Laporte A. Epidemiology of cryptococcosis in France: a 9-year survey (1985-1993). French Cryptococcosis Study Group. Clin Infect Dis 1996; 23(1): 82-90.
4. Heyderman RS, Gangaidzo IT, Hakim JG, et al. Cryptococcal meningitis in human immunodeficiency virus-infected patients in Harare, Zimbabwe. Clin Infect Dis 1998; 26(2): 284-289.
5. Bogaerts J, Rouvroy D, Taelman H, et al. AIDS-associated cryptococcal meningitis in Rwanda (1983-1992): epidemiologic and diagnostic features. J Infect 1999; 39(1): 32-37.
6. Moosa MY, Coovadia YM. Cryptococcal meningitis in Durban, South Africa: a comparison of clinical features, laboratory findings, and outcome for human immunodeficiency virus (HIV)-positive and HIV-negative patients. Clin Infect Dis 1997; 24(2): 131-134.
7. Schaars CF, Meintjes GA, Morroni C, Post FA, Maartens G. Outcome of AIDS-associated cryptococcal meningitis initially treated with 200 mg/ day or 400 mg/day of fluconazole. BMC Infect Dis 2006; 6: 118.
8. Dromer F, Mathoulin-Pelissier S, Fontanet A, Ronin O, Dupont B, Lortholary O. Epidemiology of HIV-associated crytococcosis in France (1985-2001): comparison of the pre- and post-HAART eras. AIDS 2004; 18(3): 555-562.
9. Manosuthi W, Sungkanuparph S, Thongyen S, et al. Antifungal susceptibilities of Cryptococcus neoformans cerebrospinal fluid isolates and clinical outcomes of cryptococcal meningitis in HIV-infected patients with/without fluconazole prophylaxis. J Med Assoc Thai 2006; 89(6): 795-802.
10. Saag MS, Graybill RJ, Larsan RA, et al. Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis 2000; 30(4): 710-718.
11. Bohme A, Ruhnke M, Buchheidt D, et al. Treatment of fungal infections in hematology anal oncology - guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hemotol 2003; 82 Suppl 2: S133-S140.
12. Masur H, Kaplan JE, Holmes KK. Guidelines for preventing opportunistic infections among HIV-infected persons - 2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. Ann Intern Med 2002; 137 (5 Pt 2): 435-478.
13. Berenguer J, Laguna F, Lopez-Aldeguer J, Moreno S. Prevention of opportunistic infections in adult and adolescent patients infected with the human immunodeficiency virus in the era of highly active antiretroviral therapy. Recommendations of the Grupo de Estudio del SIDA (GESIDA/Plan National sobre el SIDA). Enferm Infecc Microbiol Clin 2000; 18(9): 457-468.
14. Mofenson LM, Oleske J, Serchuck L, Van DR, Wilfert C. Treating opportunistic infections among HIV-exposed and infected children: recommendations from CDC, the National Institutes of Health, and the Infectious Diseases Society of America. MMWR Recomm Rep 2004; 53(RR-14): 1-92.
15. Gabriel 5. Cancer Pain Relief; A Guide to Opioid Availability. 2nd ed. Geneva: World Health Organisation, 1996.
16. Brouwer AE, Rajanuwong A, Chierakul W, et al. Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet 2004; 363: 1764-1767.
17. Bicanic T, Meintjes G, Woad R, et al. Fungal burden, early fungicidal activity, and outcome in cryptocaccal meningitis in antiretroviral-naive or antiretroviral-experienced patients treated with amphotericin B or flucanazole. Clin Infect Dis 2007; 45(1): 76-80.
18. Tansuphaswadikul S, Nantawat W, Phonrat B, Baanpokbn L, Mctm AG, Pitisuttithum P. Comparisan of one week with two week regimens of amphotericin B bath followed by fluconazole in the treatment of cryptococcal meningitis among AIDS patients. J Med Assoc Thai 2006; 89(10): 1677-1685.
19. Saag MS, Powderly WG, Cloud GA, et al. Comparison of amphotericin B with fluconazale in the treatment of acute AIDS-associated cryptococcal meningitis, The NIAID Mycoses Study Group and the AIDS Clinical Trials Group. N Engl J Med 1992; 326(2): 83-89.
20. Larsen RA, Leal MA, Chan LS. Fluconazole compared with amphotericin B plus flucytosine for cryptacoccal meningitis in AIDS. A randomized trial. Ann Intern Med 1990; 113(3): 183-187.
21. McCarthy KM, Margan J, Wannemuehler KA, et al. Population-based surveillance for cryptocaccasis in an antiretroviral-naive South African province with a high HIV seroprevalence. AIDS 2006; 20(17): 2199-2206.
22. Micol R, Lortholary O, Sar B, et al. Prevalence, determinants of positivity, and clinical utility of cryptococcal antigenemia in Cambodian HIV-infected patients. J Acquir Immune Defic Syndr 2007; 45: 558-559.
23. French N, Gray K, Watera C, et al. Cryptococcal infection in a cohort of HIV-1-infected Ugandan adults. AIDS 2002; 16(7): 1031-1038.
24. Desmet P, Kayembe KD, De VC. The value of cryptacoccal serum antigen screening among HIV-positive/AIDS patients in Kinshasa, Zaire. AIDS 1989; 3(2): 77-78.
25. Chang LW, Phipps WT, Kennedy GE, Rutherford GW. Antifungal interventions for the primary prevention of cryptococcal disease in adults with HIV. Cochrane Database Syst Rev 2005; 3: CD004773.
26. Pukenyte E, Lescure FX, Rey D, et al. Incidence of and risk factors for severe liver toxicity in HIV-infected patients on anti-tuberculosis treatment. Int J Tuberc Lung Dis 2007; 11(1): 78-84.
27. Cappelletty D, Eiselstein-McKitrick K. The echinocandins. Pharmacotherapy 2007; 27(3): 369-388.
28. Pfaller MA, Zhang J, Messer SA, et al. In vitro activities of voriconazole, fluconazole, and itraconazole against 566 clinical isolates of Cryptococcus neoformans from the United States and Africa. Antimicrob Agents Chemother 1999; 43(1): 169-171.
29. Scott LJ, Simpson D. Voriconazole: a review of its use in the management of invasive fungal infections. Drugs 2007; 67(2): 269-298.